Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 7, 2016, Pages 1337-1340

  Jodele, Sonata ^a   Dandoy, Christopher E ^a   Danziger Isakov, Lara ^a   Myers, Kasiani C ^a   El Bietar, Javier ^a   Nelson, Adam ^a   Wallace, Gregory ^a   Teusink Cross, Ashley ^a   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Complement blockade; Eculizumab; Hematopoietic stem cell transplant associated thrombotic microangiopathy; Meningococcal infection; Meningococcal vaccine; TA TMA

Indexed keywords

ANTIBIOTIC AGENT; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; MENINGOCOCCUS VACCINE; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RATE; MALE; MENINGOCOCCOSIS; MORTALITY; MYCOSIS; NEISSERIA MENINGITIDIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VACCINATION; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; HEMOLYTIC UREMIC SYNDROME; PRESCHOOL CHILD; PROCEDURES; TIME FACTOR;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; CHILD, PRESCHOOL; COMPLEMENT INACTIVATING AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; THROMBOTIC MICROANGIOPATHIES; TIME FACTORS;

EID: 84969174510     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.03.032     Document Type: Article

References (14)

1. Reiss U.M., Schwartz J., Sakamoto K.M., et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer 2014, 61:1544-1550.
2. Greenbaum L.A., Fila M., Ardissino G., et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016, 89:701-711.
3. Soliris [package insert] 2014, Alexion Pharmaceuticals Inc., Cheshire, CT.
4. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2013. Morbid Mortal Wkly Rep 2013, 62(RR02):1-28. Centers for Disease Control and Prevention.
5. Cullinan N., Gorman K.M., Riordan M., et al. Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 2015, 135:e1506-e1509.
6. Struijk G.H., Bouts A.H., Rijkers G.T., et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013, 13:819-820.
7. Bouts A., Monnens L., Davin J.C., et al. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011, 26:1919-1920.
8. Jodele S., Fukuda T., Mizuno K., et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016, 22:307-315.
9. de Fontbrune F.S., Galambrun C., Sirvent A., et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 2015, 99:1953-1959.
10. Kim S.S., Patel M., Yum K., Keyzner A. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion 2015, 55:452-458.
11. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
12. Parkkali T., Kayhty H., Lehtonen H., et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant 2001, 27:79-84.
13. Jodele S., Davies S.M., Lane A., et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014, 124:645-653.
14. Mahler M.B., Taur Y., Jean R., et al. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:145-149.